Innoviva (INVA) Competitors

Innoviva (NASDAQ:INVA) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Do insiders and institutionals hold more shares of INVA or IONS?

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 1.7% of Innoviva shares are owned by insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the media favor INVA or IONS?

In the previous week, Ionis Pharmaceuticals had 14 more articles in the media than Innoviva. MarketBeat recorded 20 mentions for Ionis Pharmaceuticals and 6 mentions for Innoviva. Innoviva's average media sentiment score of 1.71 beat Ionis Pharmaceuticals' score of 0.91 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ionis Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer INVA or IONS?

Innoviva currently has a consensus target price of $55.00, suggesting a potential upside of 205.90%. Ionis Pharmaceuticals has a consensus target price of $56.72, suggesting a potential upside of 97.78%. Given Innoviva's stronger consensus rating and higher probable upside, research analysts clearly believe Innoviva is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ionis Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.70

Is INVA or IONS more profitable?

Innoviva has a net margin of 18.31% compared to Ionis Pharmaceuticals' net margin of -64.25%. Innoviva's return on equity of 20.84% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	18.31%	20.84%	11.38%
Ionis Pharmaceuticals	-64.25%	-100.05%	-15.70%

Which has more volatility & risk, INVA or IONS?

Innoviva has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500.

Which has preferable earnings and valuation, INVA or IONS?

Innoviva has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$358.71M	3.14	$179.72M	$0.19	94.63
Ionis Pharmaceuticals	$705.14M	6.47	-$366.29M	-$3.04	-9.43

Does the MarketBeat Community believe in INVA or IONS?

Ionis Pharmaceuticals received 399 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 60.29% of users gave Ionis Pharmaceuticals an outperform vote while only 57.47% of users gave Innoviva an outperform vote.

Company	Underperform	Outperform
Innoviva	Outperform Votes 304 57.47%	Underperform Votes 225 42.53%
Ionis Pharmaceuticals	Outperform Votes 703 60.29%	Underperform Votes 463 39.71%

Summary

Innoviva beats Ionis Pharmaceuticals on 11 of the 19 factors compared between the two stocks.